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ABSTRACT
Objective: To investigate and compare the prevalence,
comorbidities and management of gout in practice in the
UK and Germany.
Methods: A retrospective analysis of patients with gout,
identified through the records of 2.5 million patients in UK
general practices and 2.4 million patients attending GPs or
internists in Germany, using the IMS Disease Analyzer.
Results: The prevalence of gout was 1.4% in the UK and
Germany. Obesity was the most common comorbidity in
the UK (27.7%), but in Germany the most common
comorbidity was diabetes (25.9%). The prevalence of
comorbidities tended to increase with serum uric acid
(sUA) levels. There was a positive correlation between
sUA level and the frequency of gout flares. Compared
with those in whom sUA was ,360 mmol/l (,6 mg/dl),
odds ratios for a gout flare were 1.33 and 1.37 at sUA
360–420 mmol/l (6–7 mg/dl), and 2.15 and 2.48 at sUA
.530 mmol/l ( .9 mg/dl) in the UK and Germany,
respectively (p,0.01).
Conclusions: The prevalence of gout in practice in the
UK and Germany in the years 2000–5 was 1.4%,
consistent with previous UK data for 1990–9. Chronic
comorbidities were common among patients with gout
and included conditions associated with an increased risk
for cardiovascular disease, such as obesity, diabetes and
hypertension. The importance of regular monitoring of
sUA in order to tailor gout treatment was highlighted by
data from this study showing that patients with sUA
levels >360 mmol/l (>6 mg/dl) had an increased risk of
gout flares.
Gout is a disorder of purine metabolism charac-
terised by acute, recurrent attacks of crystal
arthritis. The single most important risk factor
for developing gout is a raised level of serum uric
acid (sUA), with supersaturation of uric acid in the
extracellular fluid resulting in the precipitation of
urate crystals.1 The 5-year cumulative risk of
developing gout is 30.5% in men with an sUA
level >590 mmol/l (>10 mg/dl) and only 0.6% in
those with an sUA level ,420 mmol/l (,7.0 mg/
dl).2 Deposition of urate crystals in the articular,
periarticular and subcutaneous tissues3 results in
episodes of acute arthritis (usually initially affect-
ing the metatarsophalangeal joints) and the devel-
opment of tophi.4 In addition, deposition of urate
crystals in the renal tract may lead to impaired
renal function.
The definitive diagnosis of gout depends on
identifying monosodium urate crystals in fluid
from aspiration of an acutely affected joint.
However, joint aspiration and crystal identification
by polarising light microscopy is generally regarded
as a specialist procedure which is seldom under-
taken in general practice, where most patients with
gout are diagnosed and treated.5 6 The diagnosis is
usually made clinically, and often in retrospect,
based on clinical symptoms described by patients,
and on response to treatment.
The principal goal of treatment in chronic gout
is to prevent crystal formation and promote crystal
dissolution. Recent recommendations from the
European League Against Rheumatism (EULAR)7
state that this is most effectively achieved by
reducing and maintaining sUA levels below
360 mmol/l (6 mg/dl). Several studies provide
evidence that reduced sUA is associated with
reduced frequency of gout flares and reduction in
tophi size.3 4 8 9 Effective management requires
long-term administration of uric acid lowering
treatment, initially guided by, and then monitored
through, regular sUA testing.
A recent study in the UK demonstrated the
overall prevalence of gout to be 1.4%. Gout
prevalence increased with age and was much
higher among men.10 That study apart, however,
contemporary data on the prevalence of gout in
Europe are lacking, possibly because the episodic
and chronic nature of the condition makes these
data difficult to collect.
We therefore undertook a study to investigate
the prevalence of gout, its comorbidities, and its
current clinical management in general practice in
the UK and Germany.
METHODS
A retrospective analysis was conducted using the
IMS Disease Analyzer, a longitudinal database
containing anonymised patient records maintained
by 650 general practitioners (GPs) treating 2.5
million patients in the UK and 400 GPs and
internists treating 2.4 million patients in Germany.
Patients were included in the analysis if they had
had a consultation with a diagnosis of gout
(International Classification of Diseases (ICD-10)
code M10 or ‘‘gout’’ written in the patient notes)
between January 2000 and June 2005, and there
was at least one additional recording of gout in
their history (consultation with a diagnosis of gout
or prescription for gout treatment). Patients were
also required to have at least 24 months of
recorded data before, and 18 months after, their
index date (defined as their first consultation for
gout between January 2000 and June 2005).
Patients were excluded from the analysis if they
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were under 18 years of age or had been diagnosed with cancer.
The data analysed included comorbidities, medication use,
sUA level and frequency of flares in patients with gout.
The following definitions were used for the purposes of
identifying comorbidities: renal insufficiency (ICD-10 codes
K767, N170, N171, N172, N178, N179, N180, N188, N189,
N190 or I120; or a serum creatinine level of .150 mmol/l
(.2 mg/dl)); alcoholism (ICD-10 codes F10, Y91, Y90 or K70);
diabetes (a prescription for any antidiabetic drug; or ICD-10
codes E10, E11, E12, E13 or E14); heart failure (ICD-10 code
I500, I501 or I509); hypertension (ICD-10 codes I100, I150, I152,
I158, I159 or I270); myocardial infarction (ICD-10 codes I210,
I211, I212, I213, I214, I219, I220, I221, I228, I229 or I252); and
obesity (body mass index (BMI) .30 kg/m2; or ICD-10 codes
E660, E661, E662, E668 or E669).
Persistence was defined as the total time that any patient was
prescribed a given drug, from initiation of treatment to the end
of the last supplied prescription, without intervening discon-
tinuation of that drug.
Compliance was defined as the percentage of the prescribed
doses that could actually have been taken by a patient during
the period of persistence. Compliance was assessed by dividing
the sum of the number of days of medication supplied by the
duration of treatment while the patient was persistent (ie, the
medication possession ratio).11
A gout flare was defined as either a visit resulting in a
prescription for treating acute gout (short-term prescription
for non-steroidal anti-inflammatory drugs (NSAIDs), colchicine
or corticosteroids) or a gout-related emergency-room visit or
admission to hospital.
Mean and standard deviation were determined for all
variables during the analysis. A logistic regression model was
applied to investigate the relationship between sUA and
Table 1 Study population characteristics
Characteristics
UK
(n = 7443)
Germany
(n = 4006)
Male patients, No (%) 6074 (81.6) 3222 (80.4)
Current age (years) 65.6 (13.8) 63.1 (13.1)
Age at diagnosis (years) 61.6 (13.9) 58.6 (13.1)
Duration of gout (months) 81.4 (66.7) 67.4 (28.6)
Time of follow-up (months) 46.2 (14.4) 51.0 (14.5)
Results are shown as mean (SD) unless stated otherwise.
Figure 1 Pre-index comorbidities in (A)
the UK study population and (B) the
German study population. sUA, serum
uric acid. Conversion: sUA (mg/dl)
659.48 = mmol/l.
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frequency of gout flares. The outcome assessed was the total
number of recorded flares during the observation period (¡3–4
years), in relation to the maximum observed sUA level in that
period. Persistence was analysed using Cox regression analysis,
which models the risk of treatment discontinuation over time.
RESULTS
Gout prevalence
During the observation period, the IMS Disease Analyzer
contained 2 514 806 and 2 402 185 patient records in the UK
and Germany, respectively. Overall, there were 34 071 patients
in the UK and 34 797 in Germany who were reported to have
gout, indicating a prevalence of 1.4% in both countries. On the
basis of the inclusion and exclusion criteria, 7443 patients in the
UK and 4006 in Germany were entered into the analysis
(table 1). Over 80% of the study population was male in each of
the countries. The mean age of the patients sampled was 66
years and 63 years in the UK and Germany, respectively, and the
mean duration of gout history was 81 and 67 months,
respectively.
Pre-index comorbidities
Renal insufficiency was reported in 9.5% of the study
population in the UK and 4.8% in Germany. Figure 1 shows
the prevalence of other comorbidities within the study
population. In the UK study population, the most common
comorbidity recorded was obesity (27.7%), while in Germany it
was diabetes (25.9%). Hypertension was a common comorbid-
ity in both study populations: 18.5% of the German population
sampled and 17.5% of the UK patients had at least one record
of hypertension during the study period. Heart failure and
myocardial infarction were reported in 7.1% and 7.4% of the
UK study population, and 10.8% and 5.8% of the study
population in Germany, respectively. Alcoholism was recorded
as a diagnosis in 3% of UK patients with gout and 0.4% of the
German patients with gout. There was a trend for the
prevalence of each comorbidity to increase with sUA level (fig 1).
Drug use before and after the index consultation
Figure 2 shows drug use before and after the index consultation
in the UK and German study populations.
In the UK, 63% and in Germany 84.5% of patients with gout
received treatment (fig 2). Among these patients, allopurinol
was prescribed for most patients in both countries (89% UK;
93% Germany). Colchicine was used much less frequently (16%
UK; 15% Germany). In the UK, the use of probenecid and
sulfinpyrazone was limited to ,1% of patients receiving gout
pharmacological treatment. Benzbromarone was prescribed to
,3% of patients in Germany. In addition to chronic gout
treatment, 89.4% (UK) and 80.3% (Germany) of patients
received prescriptions for oral NSAIDs as prophylaxis.
Allopurinol was prescribed at an average daily dose of
.200 mg or (300 mg in 63.3% of patients in the UK and
65.7% of those in Germany (fig 3). Average daily doses in the
range of 50–100 mg were prescribed in 21% of patients in the
UK and 22.4% of those in Germany, and doses .300 mg/day
were not often used (2.1% of patients in the UK and 3.4% of
patients in Germany).
In the UK, persistence with allopurinol (expressed as the
percentage of patients receiving treatment for fixed time points)
was 92.3% at 28 days, 76.3% at 100 days and 61.2% by 360 days
(fig 4A). In Germany, persistence with allopurinol treatment
was 98.0% at 28 days, 54.3% at 100 days and 31.0% by 360 days
(fig 4B). Apparent rates of compliance while receiving treatment
were 93% in the UK and 96% in Germany.
sUA testing and gout flares
sUA testing was conducted during the observation period in
14% of patients in the UK and 9% of those in Germany. The
proportion of patients who had one or more sUA tests
performed annually during the observation period was ,1%
in both countries.
Overall, 72% of the study population in the UK and 41% in
Germany experienced at least one gout flare during the
observation period (table 2; 45.8%+26.2% and 17.2%+24.1%,
respectively).The mean number of gout flares per patient was
Figure 2 Drug use before and after the index consultation in (A) the UK
study population and (B) the German study population. NSAIDs, non-
steroidal anti-inflammatory drugs.
Figure 3 Average dosages of allopurinol prescribed in (A) the UK and
(B) Germany.
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1.7 in the UK and 2.9 in Germany (table 2). The frequency of
gout flares was positively correlated with the level of sUA
(table 2).
In the UK, patients with an sUA of 360–420 mmol/l (6–7
mg/dl) were 1.33 times more likely to experience a gout flare
than those in whom sUA was ,360 mmol/l (,6 mg/dl; odds
ratio (OR) = 1.33; p = NS), while those with an sUA level
>530 mmol/l (>9 mg/dl) were more than twice as likely
(OR = 2.15; p,0.01) (table 3). In Germany, patients with an
sUA level of 360–420 mmol/l (6–7 mg/dl) were 1.37 times
more likely to experience a gout flare than those in whom
sUA was ,360 mmol/l (,6 mg/dl; OR = 1.37; p = NS), and
those with an sUA level >530 mmol/l (>9 mg/dl) were more
than twice as likely to experience a gout flare (OR = 2.48;
p,0.01) (table 3).
DISCUSSION
This study was undertaken to augment the limited data
available on the epidemiology of gout and its management in
practice in Europe. The study dealt exclusively with patients
with a clinical diagnosis of gout but not patients with
asymptomatic hyperuricaemia. The overall prevalence of gout
of 1.4% was remarkably similar in two large IMS databases,
each containing about 2.5 million patient records from the years
2000–5 in Germany and the UK. The overall prevalence was also
remarkably similar to that found previously by Mikuls et al10 in
the records of 1.8 million patients in the UK General Practice
Research Database (GPRD) for the years 1990–9, using similar
case definitions.10
The consistency of these observations on the prevalence of
gout consultations in Germany and the UK would seem to
provide a measure of confidence in the robustness of estimates
of the true prevalence of gout in primary care settings in
Northern Europe. It is noteworthy, however, that the pre-
valence of gout was not greater in the current study, than in the
UK GPRD for 1990–9,10 despite the fact that the mean ages of
the patients with gout in the UK and German databases for
2000–5 were 6 years and 3 years older, respectively. The
prevalence rates observed are, however, slightly higher than
those found by Harris et al (0.95%) in 40 UK general practices in
199312 and fivefold higher than those observed (0.26%) in the
survey by Currie in UK general practices 30 years ago.13 There
are other data which suggest that the prevalence of gout might
have increased over the past 30 years. The annual prevalence of
self-reported gout in the National Health Interview Survey in
the USA trebled between 1969 and 1996,14 and the prevalence of
gout and hyperuricaemia requiring urate-lowering drug treat-
ment was observed to have increased by 80% between 1990 and
1999 in a managed-care population in the USA.15 However,
Mikuls et al showed that the overall incidence of consultations
for gout remained relatively stable throughout the 1990s,10
suggesting that any increase in prevalence might be largely
attributable to the changing age structure of the population.
Nevertheless, gout is the most common cause of inflammatory
Figure 4 Persistence with allopurinol treatment at 24 months in (A) the
UK study population and (B) the German study population.
Table 2 Frequency of gout flares during the observation period. The observation period was unique for each individual patient and depended on when
the index date occurred within the period January 2000–June 2005
All patients sUA* .7 mg/dl sUA .8 mg/dl sUA .9 mg/dl sUA .10 mg/dl
UK Germany UK Germany UK Germany UK Germany UK Germany
Patients with one gout
flare during their
observation period (%)
45.8 17.2 – – 50.3 21.4 53.0 22.3 41.9 22.4
Patients with >2 gout
flares during their
observation period (%)
26.2 24.1 – – 42.8 33.3 47.0 31.3 58.1 30.2
Mean number of gout
flares/patient
1.7 2.9 – – 1.8 3.1 1.9 3.3 1.9 3.8
Mean number of gout
flares/patient/year of
observation period
0.38 0.68 0.42 0.65 0.43 0.67 0.42 0.91 0.58 1.97
Conversion: sUA (mg/dl) 659.48 = mmol/l.
sUA, serum uric acid.
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arthritis in men over the age of 40 years,16 and the overall
prevalence of gout is notably higher than that of rheumatoid
arthritis, which was recently estimated to be 1.16% in women
and 0.44% in men across the UK population.17
As expected, the prevalence of comorbidities was high among
patients with gout in both the UK and Germany. The
comorbidities found to be most commonly associated with
gout in this study were obesity in the UK and diabetes in
Germany. Obesity was twice as common (27.7%) in UK
patients as in German patients (13.3%), while diabetes was
recorded as a comorbid diagnosis three times as often in the
German patients (25.9%) as in those in the UK GPRD (8.3%).
Similar prevalence rates of obesity have been estimated
previously in the UK and Germany,18 and the somewhat
surprising difference reported in this study may be attributable,
in part, to the use of the IMS Disease Analyzer database. In the
UK, GPs in the IMS Disease Analyzer panel can record items
such as BMI in addition to using ICD-10 codes for obesity, but
in Germany only the ICD-10 codes were considered in the study
definition of obesity as there was no other electronically coded
way for a GP to record obesity. Therefore, it is possible that
British GPs were more likely to capture information electro-
nically about obesity than those in Germany. The greater
frequency with which diabetes was recorded in Germany is
consistent with previous estimates of prevalence rates in
Europe, which were more than twice as high in Germany as
those in the UK.19
Over 60 years ago, Brochner-Mortensen observed that 78% of
a group of 100 Scandinavian patients with gout were more than
10% overweight and 57% were more than 30% overweight.20
Grahame and Scott found that 48% of a UK cohort of 354
patients with gout attending a hospital clinic were more than
15% overweight.21 Obesity was not recorded as a specific
comorbidity in the study by Mikuls et al.10 However, recently
published data demonstrated that the prevalence of abdominal
obesity and metabolic syndrome is as high as 62.9% in people
with gout identified in the US Third National Health and
Nutrition Survey (NHANES III),22 and diabetes was a comorbid
diagnosis in 19.9% of 9482 patients with gout in a North
American study of patients in a managed-care setting.23
It is therefore interesting and surprising that Mikuls et al also
found the prevalence of diabetes to be remarkably low (6.4%) in
patients with gout in their analysis from the UK GPRD for
1990–9.10 In that study, it was found that coronary artery
disease and hypertension were the most common comorbidities
in patients with gout (24.9% and 23.9%, respectively).10 The
prevalence of hypertension among patients with gout was
found to be as high as 59.7% in the North American managed-
care population.23
There is some evidence to suggest that gout and hyperur-
icaemia may be independent risk factors for cardiovascular
disease.24 25 The clinical data demonstrating the association of
gout with obesity, hypertension, excessive alcohol consumption
and metabolic syndrome is now overwhelming and incontro-
vertible.22 23 25 26 As these comorbidities are themselves major
risk factors for cardiovascular disease, every diagnosis of gout
should act as a ‘‘red flag’’ to alert doctors to assess patients for
cardiovascular risk.7 22 27
A similar proportion of patients were found to be receiving
prescriptions for diuretic drugs in the UK and Germany in this
study (, 30%), and by Mikuls et al.10 Diuretics, especially
thiazide diuretics, can increase the sUA level as a consequence of
volume depletion, increased renal tubular reabsorption of urate,
stimulation of the urate-anion exchanger (URAT-1) and a
decrease in renal urate excretion.28 Diuretic use has been found
to be a risk factor for incident gout (relative risk (RR) = 1.77;
95% confidence interval 1.42 to 2.20) which is apparently
independent of hypertension in the 12 years of follow-up of a
cohort of men who had no previous history of gout in the health
professionals follow-up study.26 However, a recent case–control
study found no evidence that diuretics were a risk factor for the
development of gout, and suggested that the cardiovascular
conditions for which they were prescribed, which are them-
selves risk factors for gout, might have confounded previous
inferences.29 This would imply that continuing flares of gout in
these patients were not primarily attributable to continuing
treatment with diuretics, but rather were a consequence of
failure to treat hyperuricaemia adequately.
Allopurinol was by far the most commonly used drug for
treating patients with chronic and interval gout in both the UK
and Germany, accounting for about 90% of all such medication.
However, despite the clear preference for allopurinol as the
preferred uric acid lowering drug, the findings from the current
study show that the management of patients with gout is
suboptimal. A large proportion of patients with gout continued
to have raised sUA levels and recurrent gout flares. Persistence
of treatment with allopurinol was remarkably low in both the
UK and Germany, but this study provides no information about
why this should have been the case.
Until recently, the importance of follow-up sUA testing to
guide treatment decisions in patients diagnosed with gout has
not been emphasised or well defined by research evidence.
However, there is now evidence from comparative randomised
controlled trials,3 30 and from an observational study in a
managed-care setting,1 that fewer than 50% of patients
receiving allopurinol, in the most commonly prescribed dose
of 300 mg daily, achieve optimum reductions in plasma urate
concentrations. Recent evidence-based, consensus guidelines
from EULAR7 emphasise the importance of ensuring that the
sUA level is maintained below 360 mmol/l (6 mg/dl), but those
from the British Society for Rheumatology27 recommend
maintaining the sUA level below 300 mmol/l (5 mg/dl).
Despite a lack of evidence for the optimum frequency for
monitoring the sUA level, recent guidelines recommend 3-
monthly measurements of sUA in the first year after the start of
treatment with uric acid lowering drug treatment followed by
Table 3 Association between serum uric acid (sUA) level and the number of flares
sUA level*
(mg/dl)
UK Germany
Odds ratio vs
sUA,6 mg/dl (CI) p Value
Odds ratio vs
sUA,6 mg/dl (CI) p Value
6–7 1.33 (0.92 to 1.94) NS 1.37 (0.91 to 2.05) NS
.7–8 1.49 (1.21 to 2.42) ,0.01 1.65 (1.17 to 2.33) ,0.01
.8–9 1.71 (1.04 to 2.13) ,0.01 2.37 (1.67 to 3.36) ,0.01
>9 2.149 (1.53 to 3.01) ,0.01 2.48 (1.77 to 3.49) ,0.01
*Conversion: sUA (mg/dl) 659.48 = mmol/l.
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annual measurements.27 The frequency of sUA testing was
found to be extremely low in this study; sUA evaluation was
performed in only 14% of the UK and 9% of the German study
populations, and fewer than 5% of patients had two sUA tests
performed in the observation period in either country. It might
be argued that it is acceptable for the sUA level to be monitored
less frequently in patients with good symptomatic control;
however, the study clearly showed that even patients who
continued to experience gout flares were not having regular sUA
checks.
Seventy-two percent of the patients with gout in the UK, and
over 40% of those in Germany, experienced at least one gout
flare, and the frequency of gout flares was significantly
correlated with sUA levels.
Previous studies have demonstrated the presence of urate
crystals in the joints of patients with asymptomatic gout,31 but
reduction of the sUA below 360 mmol/l (6 mg/dl) leads to
decreased intra-articular crystal deposition8 and more rapid
reduction of tophi3 as well as a reduction in the frequency of
gout flares.9 This suggests that maintaining the sUA level below
360 mmol/l (6 mg/dl) could prevent recurrent attacks of acute
gout in the long term.1 9 Indeed, it would be of interest to
undertake further research to investigate the possibility of a
continuous relationship between sUA levels and the risk of
crystal deposition, analogous to the relationship that has been
demonstrated between cardiovascular risk and measures such as
serum cholesterol levels and blood pressure.
This study has some limitations. Although the primary care
consultation data provided by the IMS databases are an
important source of information on the prevalence of gout,
associated comorbidities and treatment, and can provide age
and sex standardised estimates of the number of new
consultations, the IMS Disease Analyzer does not contain
community-based data that would allow for the measurement
of population-wide incidence rates of gout in different
countries. Although the IMS database populations in
Germany and the UK closely mirror the populations at large
in their male to female ratio, social class and geographical
distribution, it is possible that not all practice types are
represented.
Possibly, the study might have underestimated the prevalence
of gout in Germany, as several patients in the German database
were excluded from the analysis because they only had a single
recording of gout in their notes. Second attacks might have been
under-recorded in the German database because of the free
choice of healthcare that operates in Germany, where the doctor
responsible for the patient’s records might not be the doctor
consulted for a subsequent gout flare. There is also the
possibility that the study underestimated the frequency of gout
flares, because the option to self-medicate means not all gout
flares would necessarily have been detailed in a patient’s
records. Any such effect did not, however, prevent the study
from demonstrating a correlation between sUA level and gout
flares.
Another important question that was not dealt with was
whether the doses of allopurinol were optimum in those
patients with gout found to have a high sUA level and frequent
gout flares. The study showed that 97.9% of patients prescribed
allopurinol in the UK and 96.6% of those in Germany received
doses of (300 mg/day (fig 3), but how this was related to
outcomes was not investigated. Neither did the study evaluate
whether allopurinol doses were adjusted according to renal
function to minimise the risk of toxicity in patients with renal
impairment.27 32
The relationship between flares and the recommended7 27
prophylactic use of low-dose colchicine or NSAIDs to minimise
the risk of gout flares following the initiation of urate-lowering
treatment was not investigated.
In conclusion, this study has shown that the prevalence of
gout in practice in the UK and Germany in the years 2000–5 was
1.4%, a figure that is consistent with previous UK data for
1990–9. Patients with gout had a high frequency of chronic
comorbidities, several of which are associated with an increased
risk of cardiovascular disease. Allopurinol was the preferred
urate-lowering drug for the management of interval and chronic
gout in both countries studied, but persistence with treatment
was poor and gout flares were frequent despite urate-lowering
treatment.
Evaluation of sUA levels to guide treatment was not
undertaken sufficiently. The importance of regular monitoring
of sUA levels and adjustment of treatment to optimise sUA was
highlighted by data from this study, showing that the
prevalence of comorbidities among patients with gout was
directly related to sUA levels, and that patients with sUA levels
.360 mmol/l (.6 mg/dl) had an increased risk of gout flares.
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